Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study

By sjmartinez • October 17, 2022

Wainberg ZA, Enzinger PC, Kang YK, Qin S, Yamaguchi K, Kim IH, Saeed A, Oh SC, Li J, Turk HM, Teixeira A, Borg C, Hitre E, Udrea AA, Cardellino GG, Sanchez RG, Collins H, Mitra S, Yang Y, Catenacci DVT, Lee KW. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2022 Oct 13:S1470-2045(22)00603-9. doi: 10.1016/S1470-2045(22)00603-9. Epub ahead of print. PMID: 36244398.

Tags: Digestive Diseases, Hematology/Oncology, Publications

Reply to Huang et al

Dong TS, Chang L. Reply to Huang et al. Gastroenterology. 2024 Dec 20:S0016-5085(24)05800-1. doi: 10.1053/j.gastro.2024.12.009. Epub ahead of print. PMID: 39710344.

FAAHcilitating recovery in malnourished kids

Chandra F, Hsiao EY. FAAHcilitating recovery in malnourished kids. Cell Chem Biol. 2024 Dec 19;31(12):2018-2020. doi: 10.1016/j.chembiol.2024.11.007. PMID: 39706166.

Small Molecules, Big Results: How JAK Inhibitors Have Transformed the Treatment of Patients with

Fansiwala K, Sauk JS. Small Molecules, Big Results: How JAK Inhibitors Have Transformed the Treatment of Patients with IBD. Dig Dis Sci. 2024 Dec 20.[...]